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sClinical presentation
A 36-year-old male was referred to the Maxillofa-
cial Surgery outpatient’s clinic by the ENT doctor
because of a palatal and submandibular swelling.741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.09.003
* Corresponding author. Tel.: +31 104 633 302; fax: +31 104
33 098.
E-mail address: m.koudstaal@erasmusmc.nl (M.J. Koud-
taal).The patient stated that the palatal swelling had
been there since the extraction of a maxillary mo-
lar, nine months prior to his visit to our clinic. The
lesion had increased in size and was painful. There
had been no bleeding or purulent discharge from
the lesion. The submandibular swelling was noted
by the patient five months earlier and had also
slowly increased in size. The patient had lost two
kilograms in weight in five months. On examination
there were several painless, firm and mobile lymphved.
Figure 1 The intra-oral swelling on the left hard
palate. The mucosa was intact and of normal texture.
We apologize for the poor quality.
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largest dimension measuring from 1 to 3 cm. The
intra-oral swelling was firm and immobile. It was
located on the left hard palate and its largest
dimension was 3 cm. The swelling had a blue-gray
appearance the overlying mucosa was intact and
had a normal texture (Fig. 1). Further clinical
examination yields no other pathological findings.
The panoramic X-ray did not show any evidence
of bone involvement. The medical history of the
patient mentioned a Bell’s palsy two years prior
to the onset of the present lesions. The patient
was not on any medication.Differential diagnosis
The clinical differential diagnosis in our case with
the palatal swelling includes soft tissue tumors like
lymphomas of the palate (non-Hodgkin’s lymphoma
or malignant histiocytosis),1 benign minor saliva-
tory gland tumors (e.g. pleomorphic adenoma),
malignant minor salivatory gland tumors (e.g.
mucoepidermoid carcinoma, adenoid cystic carci-
noma, acinic cell adenocarcinoma), palatal ab-
scesses, myeloid leukemia (e.g. acute myeloid
leukemia, or chronic myeloid leukemia) and acute
lymphoblastic or monocytic leukemia. Rare entities
like Kaposi’s sarcoma, squamous cell carcinoma,2,3
benign lympho-epithelial lesion of the palate and
‘‘tumor-like’’ lesions such as haemangioma should
also be considered.
Although tumors of the salivatory glands are
uncommon, they are by no means rare. The most
common site for salivatory gland tumors is the par-otid gland, accounting for 64–80% of all cases. A
relatively low percentage, 15–32%, of these tu-
mors are malignant. 8–11% occur in the subman-
dibular gland, but the frequency of malignancy is
37–45%. Tumors of the sublingual glands are rare,
comprising only 1% of all salivary neoplasms but
70–90% are malignant. The palate is the most
frequent site for minor salivatory gland tumors,
42–54% of all cases. They mostly occur on the pos-
terior lateral hard or soft palate, which have the
greatest concentration of glands. The most fre-
quently found tumors of the minor salivatory glands
are the mucoepidermoid carcinoma, adenoid cystic
carcinoma and acinic cell adenocarcinoma.4
Because the patient did not exert any fever an
inflammatory origin (abscess) was ruled out. Since
the tumor was not localized (the combination of
the palatal lesion with the submandibular lymph
nodes), benignant tumors (e.g. pleomorphic
adenoma, benign lympho-epithelial lesion and hae-
mangioma) were unlikely. The blue-gray appear-
ance of the palatal lesion made the diagnosis of
pleomorphic adenoma even less likely. The firm-
ness of the palatal lesion and the fact that needle
aspiration did not provide blood or puss ruled out
the diagnosis of an abscess or haemangioma. Malig-
nant histiocytosis and squamous cell carcinoma
were less likely since the palatal mucosa overlying
the tumor was intact without signs of ulceration.
Virological examination revealed the patient to
be HIV negative making the diagnosis of Kaposi’s
sarcoma less likely.
Fine needle aspiration from a submandibular
lymph node did not provide enough tissue for diag-
nosis so a lymph node from the right submandibular
region (level II) was removed and sent in for histo-
logical examination. An incisional biopsy was taken
from the palatal lesion and was sent for histological
examination after standard pathological process-
ing. The tissue was fixed in 10% neutral buffered
formalin and embedded in paraffin after overnight
tissue processing. Sections of four micrometers
were cut, mounted on glass slides and stained with
hematoxylin/eosin (HE) for standard pathological
examination. Additional immunohistochemical
staining were performed according to standard
two step procedures using commercially obtained
antibodies against the various receptor molecules
in the cell and on the cell surface.Diagnosis
Histological examination of both the palatal and
the submandibular specimen showed a dense
72 M.J. Koudstaal et al.cellular infiltrate extending form just under the epi-
thelial layer till deep into the soft tissues (Fig. 2).
The cells have a moderately amount of cytoplasm
and a round to ovally shaped, slightly polymorphic
nucleus with inconspicuous nucleoli (Fig. 3). The
nuclear chromatin pattern was relatively fine.
Histological differential diagnosis includes his-
tiocytic or lymphocytic lymphoma.5 The tumor
cells did not have a characteristic phenotype and
may mimic cells of a large number of other tumors,Figure 2 Histological specimen showing a dense cellu-
lar infiltrate extending form just under the epithelial
layer till deep into the soft tissues. Note the massive
infiltration in the stroma beneath the epithelial lining
which is not affected by the tumor (bottom of the
image). HE staining. Original object lens magnification
2.5·.
Figure 3 Larger magnification of the lesion demon-
strating the characteristics of the cells and nuclei (see
text). HE staining. Original object lens magnification
40·.especially when morphologic variants are involved.
Among the tumors to be considered are amelanotic
melanoma, alveolar rhabdomyosarcoma or plas-
macytoma,6 small-cell carcinoma, epidermoid
carcinoma, sarcoma, cystosarcoma, phylloides,
eosinophillic granuloma, atypical carcinoid,
microglioma, Ewing’s sarcoma, multiple myeloma,
immunoblastic sarcoma, reticulum cell sarcoma.7
To make a final diagnosis a panel of antibodies
was used in immunohistochemical staining proce-
dures. The tumor cells did not stain with antibodies
against pan-keratin, keratin 7, keratin 20, NCL5D3,
CEA or EMA, making the diagnosis of carcinoma
very unlikely. A melanoma was excluded with a
negative staining for S100, HMB 45 and Melan A. A
negative CD79a, and CD138 practically excluded a
B lymphoma, including a plasmacytoma. A T-cell
non-Hodgkin’s lymphoma was very unlikely be-
cause the CD2, CD3, CD5 and CD8 were negative.
A negative CD30 and ALK-1 practically excluded
an anaplastic large cell lymphoma. The tumor
was however positive for CD 45 and in combination
with the morphological features of the tumor cells
the possibility of granulocytic sarcoma was raised,
notwithstanding the fact that the Leder’s stain was
negative. This was confirmed by a positive staining
for CD43, HLA-DR and CD4 (partially) (Fig. 4). The
negative staining for CD34, CD 117, MPO, lysozyme,
glycophorin C, Factor VIII, Ulex Europeus makes a
monocytoid differentiation the most likely. This is
also supported by the negative Leders’s stain. This
was confirmed by the flowcytometric analysis of
the lymph node exhibiting CD45 and CD33 weakly,
demonstrating positivity for CD117, CD56, CD13
and HLADR, while negative for CD34, cyMPO,Figure 4 Positive immunohistochemical staining of the
tumor cells with antibodies against CD43. Counterstain-
ing of the nuclei was achieved with haematoxylin.
Original object lens magnification 40·.
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tion of the granulocytic sarcoma revealed complex
karyotypic abnormalities, rendering the illness to a
poor risk category.
The blood cell count revealed hemoglobin 9.3
mmol/l (8.6–10.5 mmol/l), platelets 471 · 109/l
(150–370 · 109/l), leukocytes 7.8 · 109/l [3.5–
10.0 · 109/l] with a normal differentiation. Virolog-
ical examination revealed the patient to be HSV,
HIV negative, HbsAg negative and anti HBc nega-
tive. Further laboratory examination revealed no
hepatic nor renal disturbances and no signs of dis-
seminated intravascular coagulation were estab-
lished. A morphological smear of the iliac crest
did not reveal an excess of blasts (4.2% of nucle-
ated cells), the bone marrow biopsy showed a
trilinear hematopoiesis without an increase in
blasts. Cytogenetic and molecular diagnostic stud-
ies (AML1-ETO and CBFB-MYH11) from the bone
marrow demonstrated no abnormalities. Immuno-
logical examination by flowcytometry, however,
of the bone marrow revealed a undifferentiated
myeloid population with the same immunological
phenotype as was previously established on the le-
sion of the palate (markers used for minimal resid-
ual disease were CD34 negative, CD117 positive,
weak expression of CD45 and positivity for CD56).
This demonstrates a small amount of leukemic
blasts in the bone marrow, which do not reach
the criteria of an acute myeloid leukemia, because
the percentage of blasts did not exceed 20%. In
addition, a morphological examination of the cere-
brospinal fluid demonstrated the presence of blas-
tic cells. CT-scan showed multiple enlarged
cervical lymph nodes at levels one through five of
the neck on the right side with the largest about
3 cm in diameter. There was a hepatomegaly of
20 cm on the CT-scan.
This led us to conclude that the final diagnosis
was granulocytic sarcoma in the left hard palate
and right submandibular region, with a small num-
ber of leukemic blasts in the bone marrow and the
central nervous fluid.Clinical course and management
The patient was referred to the department of
Hematology. The patient received two session
of chemotherapy (first course: idarubicine
1 · 12 mg/m2 on day 1–3, arabinosyl–cytosin
200 mg/m2 continuous on day 1–7; second course:
arabinosyl–cytosin 2 · 1000 mg/m2 day 1–6 and
amsacrine 1 · 120 mg/m2 day 1, 3 and 5). Intrathe-
cal methotrexate 15 mg and dexamethason 4 mgwas administered ten times because of the positive
liquor, which became negative on this treatment.
Because of the poor risk features of the granulo-
cytic sarcoma a search for an allogeneic donor
was undertaken, but no HLA-identical siblings or
‘‘matched unrelated’’ donors (MUD-donor) could
be identified. Since there was no donor available
for an allogeneic stem cell transplantation the pa-
tient received a third course of chemotherapy. The
therapy was complicated by ARA-C toxicity, Asper-
gillus pneumonia, and a paronychia of the right
hallux. Because of the central nervous system
localization the patient received adjuvant radio-
therapy (2 Gy, 15 fractions) of the brain and neck
after the three courses of chemotherapy. There
were no radiotherapy-related complications.
The disease went into complete remission for
two years. But recently a bone marrow relapse
was diagnosed, for which the patient is currently
reinduced with high dose chemotherapy in order
to perform an autologous or, if a MUD-donor
can be located, an allogeneic stem cell
transplantation.Discussion
Granulocytic sarcoma (chloroma) is an extramedul-
lary-localized tumor mass composed of immature
cells of the granulocytic lineage (myelocytes).
Burns reported the first case in 1811.8 In 1853, King
used the term chloroma because the tumor exhib-
ited a greenish color that faded on exposure to
the air, which was produced by the presence of
myeloperoxidase (verdoperoxidase) in the tumor
cells.9 The present term granulocytic sarcoma is
more appropriate since the tumor is not always
green, is composed of immature cells of the granu-
locytic lineage, and resembles a sarcoma.6 Granu-
locytic sarcoma can appear in various sites
including the skin, gingiva, lymph nodes, bone, soft
tissue, and visceral organs.6,10,11 The tumor is
capable of local tissue destruction and invasion.1
Granulocytic sarcomas are thought to arise in
the bone marrow and travel via the Haversian ca-
nals to reach the subperiosteal region of bone.
Once in the periosteum, the tumor cells can spread
to other parts of the body.1,12 The association of
granulocytic sarcoma with leukemia was first made
in 1892 by Dock.1,13 It has most frequently (2.9–8%)
been reported with the monocytic form of acute
myelogenous leukemia (AML M5) but also associa-
tion with chronic myelogenous leukemia (3.9%)
and at the onset of a blast crisis in chronic myelog-
enous leukemia is reported (4.2%).6,10,14 Several
74 M.J. Koudstaal et al.cases are reported without detectable evidence of
leukemia in the peripheral blood or bone mar-
row.6,15 The granulocytic sarcoma may precede
the manifestations of AML by months or years.
The pathological diagnosis of granulocytic sar-
coma should be made on both histological and
(immuno)histochemical grounds. In the HE staining
of optimally fixed, processed, embedded and cut
tissue, one should observe at least blasts, with a
high nuclear/cytoplasmic ratio and more or less
round nuclei with a diameter of approximately
twice the diameter of a normal lymphocyte. The
chromatin should be relatively fine. Course chro-
matin pattern usually indicates a blast of lympho-
genic origin. To refine and confirm the
morphological differential diagnosis, immunohisto-
chemistry is imperative when, as in this case, the
histochemical Leder’s (chloro-acetate esterase)
stain does not demonstrate the granules in the
cytoplasm. The Leder’s stain is often if not always
negative if the lesion demonstrates (complete) dif-
ferentiation which is not myelogenic or when the
lesion consists of very immature blasts. Alterna-
tively, flowcytometry may also be used when fresh
tissue is available.
When relying on immunohistochemistry to con-
firm the histological diagnosis, one may start with
confirmation of haematological origin by demon-
strating a positive staining for CD45. Additionally,
one or more of the markers indicative of a myeloid
origin are usually positive: myeloperoxidase (MPO),
lysozyme, CD13, CD 14, CD33, CD34, CD68 and
CD117.
It is remarked that CD13, CD14 and CD33 are
only available for use on frozen sections, while
CD117 is also positive for a GIST (gastrointestinal
stromal cell tumor). Therefore, in practice a posi-
tive staining of a combination of these markers to-
gether with the compatible morphology is used to
make the diagnosis: CD34, CD43, CD4, MPO, lyso-
zyme, glycophorin C.
A positive CD43 staining is important in making
the diagnosis of granulocytic sarcoma in a number
of cases, especially when other myeloid markers
such as MPO does not stain However, this is only
the case in the context of a negative staining pat-
tern for a panel of markers, which are specific
and sensitive enough for of B and T cells. The same
goes for CD4.16
We use glycophorin C as glycophorin A does not
stain all the erythroid precursors and thus does
not give a complete picture of the erythopoieses
in a bone marrow biopsy.17 More importantly,
malignancies derived from erythroid precursor
may have a higher chance to be false negatively
stained with glycophorin A.In practice, it may be necessary to also exclude
other tumors in the morphological differential
diagnosis with negatively staining antibodies. This
include carcinoma’s (negative keratins), amela-
notic melanoma (negative S100 and MelanA),
anaplastic large cell lymphoma, small cell variant
(negative CD30 and ALK-1), B-cell lymphoma’s
(negative CD20, CD79a and CD138), and T cell lym-
phoma’s (negative CD1a, CD2, CD3, CD5, CD8 and if
necessary granzyme B and TIA-1).18
Oral manifestations of acute leukemia are
well documented in literature.19,20 The myeloid
leukemias are usually of medullary origin with
primary dissemination of immature blast cells in
various tissues of the body.21 Extramedullary
tumors occurring before or during myeloid
leukemia were termed granulocytic sarcomas,
leukocytic sarcomas, chloromas or myelosar-
comas.
In literature there are several reported cases of
facial nerve paralysis as the presenting symptom
of leukemia.22–26 In these cases the actual loca-
tion of the tumor caused the facial nerve palsy
through compression. The medical history of our
patient mentioned a Bell’s palsy two years prior
to the onset of malignancy. The location of the
granulocytic sarcoma (neck and palate) and the
elapsed period of time between the nerve palsy
and the onset of the malignancy can, in our opin-
ion, does not explain the facial nerve palsy.
Therefore we conclude that the Bell’s palsy in
our case was coincidence.
A structural search of the literature (Medline)
was performed and showed only thirty-six cases
of granulocytic sarcoma in the oral cavity re-
ported from 1883 until now, of which five were
situated on the hard palate. The patient date of
the previously reported cases and the case pre-
sented here are listed in Table 1. The clinical fea-
tures of the granulocytic sarcoma the oral cavity
reported are diverse. The most frequently re-
ported clinical presentation of the tumor is of a
firm swelling with either a bluish, brownish, red-
dish, black-pigmented or gray-white color with
intact overlying mucosa. Several authors describe
nodular exophytic growing lesions with or without
ulceration and bleeding. Others report non-heal-
ing extraction sockets with a polypoid mass grow-
ing from it. Also a purulent apical lesion has been
described to be the clinical presentation of the
granulocytic sarcoma. Of the five reported palatal
lesions three presented themselves as a firm
gingival swelling with intact overlying muco-
sa,29,39,48 one with a bulging bosselated surface37
and one with an exophytic, ulcerated gray-white
lesion.15
Table 1 Reported cases of granulocytic sarcoma (GS) in the oral cavity
Authors/year Age Sex Location Type of
maliganancy
Time of diagnosis
of leukemia
Chiari27 6 M Left maxillary AB NR NR
Brooks et al.28 8 M Right maxillary sinus AML 4 years after GS
Neiman et al.29 NR NR Soft palate NR NR
Hansen et al.30 83 F Right maxillary AB AML 3 months after GS
Conran et al.31 2 F Right mandible DF 16 months after GS
Takagi et al.32 25 F Left mandible AML 18 months after GS
Reichart et al.21 35 F Right mandible AML 3 months after GS
Castella et al.15 89 F Left hard palate DF NR
Welch et al.33 3 F Left maxillary sinus DF NR
Timmis et al.34 52 M Left mandible LL Directly with GS
Muller et al.35 37 F Tonsil AML 6 years before GS
39 F Tonsil DF NR
Ficarra et al.6 67 F Right hard palate AML 15 months after GS
Saleh et al.36 62 F Right mandible AML Directly with GS
Dreizen et al.37 NR NR Left hard palate NR NR
Ferguson et al.38 69 M Right epiglottis CML 3 years before GS
Barker and Sloan39 4 F Left maxillary AB and palate AML 1 year before GS
Alessi et al.40 6 F Right maxillary AB and sinus AML 2 years before GS
Rodriquez et al.7 56 M Left mandible AML 5 months after GS
Cho et al.41 3 M Right mandible AML 2 years before GS
Eisenberg et al.5 33 M Right maxillary/mandibular AB AML Directly with GS
Stack and Ridley42 70 M Right mandible CML Directly with GS
Ritter et al.43 41 F Mandibular gingiva AML Before GS (time NR)
Tuset et al.44 77 M Right mandible MDS 2 months before GS
Roth et al.18 47 M Gingiva (location NR) AML Directly with GS
Wiernik et al.45 1 M Mandible (location NR) AML 22 months before GS
19 M Gingiva (location NR) AML 15 months before GS
56 M Gingiva (location NR) AML 15 months before GS
5 F Left mandibular gingiva AML 21 months before GS
Lynch et al.46 86 F Left maxillary gingiva AML 29 months after GS
Carmona et al.47 60 F Right mandible CML 2 years before GS
Tong and Lam3 76 F Right maxillary AB AML 7 months after GS
Lee et al.12 43 F Left maxillary AB NR NR
Amin et al.48 58 M Left hard palate AML Directly with GS
Jordan et al.49 62 F Apical teeth number 41 AML 6 weeks after GS
Asna at al.50 72 F Tongue MDS NR
Present case 36 M Left hard palate AML Directly with GS
Abbreviations: AML: acute myelogenous leukemia; NR: not reported; AB: alveolar bone; DF: disease free; LL: lymphocytic lym-
phoma; CML: chronic myelogenous leukemia; MDS: myelodysplastic syndrome.
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cavity is a rarely occurring entity. The oral diagnos-
tician is confronted with a diagnostic challenge,
when it presents itself as a solitary lesion, often
well in advance of other the clinical and laboratory
findings indicating a leukemia. This challenge is
equal for both the physician and the pathologist.
The tumor is often misdiagnosed as lymphoma11
or no diagnosis is reached before the onset of other
clinical manifestations. The myeloid origin of these
cells can be established with a histochemical Le-
der’s (chloro-acetate esterase) staining, flowcy-
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